



## Source

Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is a mouse monoclonal antibody produced from hybridoma.

## Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).

## Clone

Y45

## Species

Mouse

## Isotype

Mouse IgG1/kappa

## Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

## Immunogen

Recombinant FMC63 scFv derived from HEK293 cells.

## Conjugate

Unconjugated

## Isotype Control

The Isotype control is sold separately and you can search for Cat. No. [DNP-MIAI](#) for product information.

## Recommended Dilution

1:50

## Formulation

Lyophilized from 0.22  $\mu$ m filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

## Reconstitution

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

## Storage


For long term storage, the product should be stored at lyophilized state at  $-20^{\circ}\text{C}$  or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- $-20^{\circ}\text{C}$  to  $-70^{\circ}\text{C}$  for 24 months in lyophilized state;
- $-70^{\circ}\text{C}$  for 12 months under sterile conditions after reconstitution.

## Bioactivity-FACS



$2 \times 10^5$  of anti-CD19 CAR-293 cells were stained with 100  $\mu$ L of 1:50 dilution (2  $\mu$ L stock solution in 100  $\mu$ L FACS buffer) of Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-Y45) and Isotype control antibody respectively. PE signal was used to evaluate the binding activity (QC tested).

Discounts, Gifts,  
and more!





## Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

## Clinical and Translational Updates

Discounts, Gifts,  
and more!

